Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

American Journal of Cardiology

Volumn 110, Issue 6, 2012, Pages 826-833

  Patil, Harshal R ^a,b   Al Badarin, Firas J ^a,b   Al Shami, Hamza A ^b   Bhatti, Salman K ^a   Lavie, Carl J ^c,d   Bell, David S H ^e   O'Keefe, James H ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; VOGLIBOSE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84865492997     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.04.061     Document Type: Article

References (30)

1. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, R. Sherwin, B. Zinman American Diabetes Association European Association for Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
2. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement Quality of Reporting of Meta-Analyses Lancet 354 1999 1896 1900
3. Sponsors and Collaborators Bristol-Myers Squibb Investigators Study of BMS-477118 as monotherapy with titration in subjects with type 2 diabetes who are not controlled with diet and exercise Last update November 20, 2009 http://ClinicalTrials.gov/show/NCT00316082 Accessed October 10, 2011
4. D. Williams-Herman, J. Johnson, R. Teng, G. Golm, K.D. Kaufman, B.J. Goldstein, J.M. Amatruda Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes Diabetes Obes Metab 12 2010 442 451
5. A. Schweizer, A. Couturier, J.E. Foley, S. Dejager Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-nave patients with type 2 diabetes Diabet Med 24 2007 955 961
6. A. Schweizer, S. Dejager, E. Bosi Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial Diabetes Obes Metab 11 2009 804 812
7. J. Rosenstock, M. Niggli, M. Maldonado-Lutomirsky Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-nave patients with type 2 diabetes mellitus Diabetes Obes Metab 11 2009 571 578
8. J. Rosenstock, C. Aguilar-Salinas, E. Klein, S. Nepal, J. List, R. Chen CV181-011 Study Investigators Effect of saxagliptin monotherapy in treatment-nave patients with type 2 diabetes Curr Med Res Opin 25 2009 2401 2411
9. F.X. Pi-Sunyer, A. Schweizer, D. Mills, S. Dejager Efficacy and tolerability of vildagliptin monotherapy in drug-nave patients with type 2 diabetes Diabetes Res Clin Pract 76 2007 132 138
10. A. Pftzner, E. Paz-Pacheco, E. Allen, R. Frederich, R. Chen CV181039 Investigators Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks Diabetes Obes Metab 13 2011 567 576
11. J.E. Foley, S. Sreenan Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-nave patients with type 2 diabetes Horm Metab Res 41 2009 905 909
12. R.A. DeFronzo, P.R. Fleck, C.A. Wilson, Q. Mekki Alogliptin Study 010 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 31 2008 2315 2317
13. P. Aschner, H.L. Katzeff, H. Guo, S. Sunga, D. Williams-Herman, K.D. Kaufman, B.J. Goldstein Sitagliptin Study 049 Group Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes Diabetes Obes Metab 12 2010 252 261
14. E. Bosi, F. Dotta, Y. Jia, M. Goodman Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus Diabetes Obes Metab 11 2009 506 515
15. J.C. Chan, R. Scott, J.C. Arjona Ferreira, D. Sheng, E. Gonzalez, M.J. Davies, P.P. Stein, K.D. Kaufman, J.M. Amatruda, D. Williams-Herman Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Diabetes Obes Metab 10 2008 545 555
16. A study assessing saxagliptin treatment in subjects with type 2 diabetes who are not controlled with diet and exercise Last update June 3, 2011 http://ClinicalTrials.gov/show/NCT00374907 Accessed October 10, 2011
17. J.E. Foley, M.C. Bunck, D.L. Mller-Goede, M. Poelma, G. Nijpels, E.M. Eekhoff, A. Schweizer, R.J. Heine, M. Diamant Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial Diabetologia 54 2011 1985 1991
18. Long-term safety study of alogliptin in participants with type 2 diabetes in Japan Last update February 1, 2012 http://ClinicalTrials.gov/show/ NCT01263496 Accessed October 10, 2011
19. Evaluate saxagliptin in adult Indian patients with type 2 diabetes inadequate glycemic control Last update August 18, 2011 http://ClinicalTrials. gov/show/NCT00918879 Accessed October 10, 2011
20. Evaluate efficacy and safety of saxagliptin in adult patients with type 2 diabetes inadequate glycemic control Last update August 17, 2011 http://ClinicalTrials.gov/show/NCT00698932 Accessed October 10, 2011
21. K.N. Garratt, P.A. Brady, N.L. Hassinger, D.E. Grill, A. Terzic, D.R. Holmes Jr Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 33 1999 119 124
22. S.E. Nissen, K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
23. R. Frederich, J.H. Alexander, F.T. Fiedorek, M. Donovan, N. Berglind, S. Harris, R. Chen, R. Wolf, K.W. Mahaffey A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes Postgrad Med 122 2010 16 27
24. O.E. Johansen, D. Neubacher, M. von Eynatten, S. Patel, H.J. Woerle Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 11 2012 3
25. W.B. White, G.L. Bakris, R.M. Bergenstal, C.P. Cannon, W.C. Cushman, P. Fleck, S. Heller, C. Mehta, S.E. Nissen, A. Perez, C. Wilson, F. Zannad EXamination of CArdiovascular OutcoMes with AlgliptIN versus standart of CarE in patients with type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome Am Heart J 162 2011 620 626.e1
26. D. Williams-Herman, S.S. Engel, E. Round, J. Johnson, G.T. Golm, H. Guo, B.J. Musser, M.J. Davies, K.D. Kaufman, B.J. Goldstein Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes BMC Endocr Disord 10 2010 7
27. J.J. Neumiller, L. Wood, R.K. Campbell Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus Pharmacotherapy 30 2010 463 484
28. J.H. O'Keefe, N.M. Gheewala, J.O. O'Keefe Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health J Am Coll Cardiol 51 2008 249 255
29. S.P. Marso, J.B. Lindsey, J.M. Stolker, J.A. House, G. Martinez Ravn, K.F. Kennedy, T.M. Jensen, J.B. Buse Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies Diabetes Vasc Dis Res 8 2011 237 240
30. L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, D. Elahi, R.P. Shannon Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965